Eve Wellbeing Weekly Scan — 2026-10-21

Standing policy: 2026-10-04-eve-wellbeing-reading-protocol. No diagnosis, no prescription, no medication advice — the guidelines below are recorded as evidence landscape, not as advice for anyone. Young's agreed 1–2 weekend beers as wind-down stands, untouched. Modern lane only; never blended with 2026-09-22-kushi-corpus-map.

Two-day interval since 2026-10-19-eve-wellbeing-weekly-scan, so this pass is weighted toward closing that scan's queued verification item (the Lancet alcohol paper — closed, §3.1) and a rare structural event on the menopause thread: a second guideline converging with the first (§2.1).

1. New episodes since the 2026-10-19 scan

All six feeds re-fetched; item counts: On Purpose 890, Rangan 685, Happiness Lab 280, WCDHT 649, Mel Robbins 448, Life Kit 268 (no new Life Kit items). Descriptions were read in full for every candidate before these calls (protocol: no bare-title calls).

Kept #1 — Happiness Lab: knowledge–action gap (Ethan Kross), 19 Oct

Identity checks out: Kross is Professor of Psychology at the University of Michigan, director of the Emotion & Self-Control Lab; Shift: Managing Your Emotions — So They Don't Manage You is a real 2025 book. This is a self-aware live episode (recorded at SXSW): happiness researchers who fail to follow their own advice, and the psychological biases behind that gap. The resources list is real academic work (Kross's Chatter 2021 and Shift 2025; Santos & Gendler's "Knowing is Half the Battle"; Oettingen, Morewedge, Solomon's-paradox self-distancing work). Fits standing mental-clarity lane: knowing does not equal doing, and the tools are body / attention / space / relationship based. Nothing outlandish in the framing to trace; the episode is a faithful summariser.

Kept #2 — Mel Robbins: Mayo Clinic dermatologist (Dr Saranya Wyles), 19 Oct

Identity checks out: Wyles is an MD/PhD dermatologist at Mayo Clinic, Associate Professor, director of the Regenerative Dermatology & Skin Longevity Lab, with a research focus on cellular senescence in skin ageing and wound healing (senolytics, 3D bioprinted skin, inflammaging). Editorial framing in the show notes ("amazing skin", what's "worth your money") is promotional — treated as marketing copy per protocol. The genuinely scientific core is real: skin as a window on systemic inflammation ("check engine light"), inflammaging, senescence. Specific "5 habits" claims are show-notes level only and were not traced this pass — parked in §4. Plausibly useful for the sleep/circadian/morning-light thread (sunscreen, light, inflammation), but no statistic repeated here.

2. New primary evidence traced this pass

2.1 ACOG Clinical Practice Guideline No. 13 — menopausal VMS, sleep, mood

Published online 15 Oct 2026 in Obstetrics & Gynecology (Contemp OB/GYN secondary coverage read; replaces Practice Bulletin No. 141 from Jan 2014). This is the week's structural event: a second independent guideline converging with the ACP review from 2026-10-19 (§2.1 there).

• Systemic MHT (estrogen+progestogen with uterus; estrogen alone without) — strong recommendation, moderate-quality evidence, for both VMS and vasomotor-related sleep disturbance.
• Meta-analysis cited: estrogen ± progestogen reduced VMS frequency (RR 0.43) and severity (RR 0.29); network meta-analysis of 32 RCTs ranked transdermal estradiol + progestogen most effective for VMS frequency.
• Sleep: meta-analysis of 15 RCTs (N = 27,715) — MHT improved self-reported sleep quality (SMD −0.13) but not objective polysomnography measures. That gap (self-report vs objective) echoes the OPTION-VMS actigraphy story from 10-19 and is worth watching as the thread matures.
• Pooled safety: no increase in breast/endometrial cancer, VTE, stroke or CHD vs placebo — with follow-up extending only to 2 years, stated plainly.
• OASIS 1 (elinzanetant, n = 396): 12-week reductions in VMS frequency and sleep disturbance vs placebo; liver testing recommended at baseline and 3 months.

Convergence reading: two independent bodies (ACP 6 Oct, ACOG 15 Oct) landing the same direction within nine days is the most robust signal this lane has produced since the protocol-stage RCTs. It strengthens the perimenopause → night-awakening thread's infrastructure, while the ACP-level limit still holds: only 8 of 90 trials were in perimenopausal women specifically. It is a guideline for clinicians, not a personal recommendation for anyone.

2.2 Sleep drives inflammation? Genetic evidence ( Sleep, 14 Oct 2026)

Sleep, advance article zsag254, 14 Oct 2026, 10.1093/sleep/zsag254 (primary abstract read via the journal's advance-articles listing). Genetic pleiotropy study linking insomnia and C-reactive protein: shared causal variants suggest insomnia is not only associated with inflammation but may actively drive it — implicated genes cluster in synaptic function, immune signalling, cellular stress response and chromatin regulation.

• Advances the standing sleep ↔ chronic-inflammation loop from correlation toward (genetically-informed) causal direction. Genetic instrument evidence carries its own caveats (pleiotropy assumptions), so this is direction-of-effect support, not a measured effect size.
• Converges with the immune-ageing stack already on record (2026-10-19 §2.6 cortisol→epigenetic-age via immune composition; Cell Genomics interferon-MR mechanism from 10-12).

2.3 Insomnia × lifetime stress interact on amyloid (Co-STAR cohort)

J Neurol (10.1007/s00415-026-14102-7), n = 124 memory-clinic patients without dementia, CSF biomarkers, cross-sectional. Greater lifetime stressor exposure was associated with lower CSF Aβ42 (i.e. greater brain amyloid accumulation) only among those with moderate-to-high insomnia scores; no interaction for tau. Stress exposure alone showed no direct association. Small, cross-sectional, selected memory-clinic sample — but it is the first interaction finding this lane has recorded where sleep disturbance acts as the permissive condition for stress exposure's association with amyloid. Fits the carer-under-load framing (chronic stress plus fragmented sleep) as a pattern, explicitly not as any individual's risk statement.

2.4 Non-hormonal sleep RCT for low-VMS menopausal women (NCT07375095)

Menopause journal, 10.1097/gme.0000000000002880, randomised double-blind placebo-controlled, n = 128 randomised / 127 completed, 3-week arm. A "neurotransmitter-modulating supplement" (L-theanine, GABA, magnesium, SAMe) improved self-reported sleep disturbance (PROMIS SD LS difference −11.1) and sleep-related impairment vs placebo in perimenopausal/postmenopausal women with significant sleep disturbance but minimal hot flashes; total sleep time +40.9 min vs −14.9 min on placebo (diary-based).

• Read with the usual supplement caution: industry-adjacent product, 3-week acute window, self-reported primary outcomes plus diary sleep, and the magnitude of the diary effect (40 min I would want replicated) is unusually large for this class of ingredient.
• Sleep-maintenance framing (WASO-driven, GABA-B/melatonin mechanism) is biologically coherent with the nonvasomotor-sleep-disturbance point above, but mechanism talk here is preclinical rodent work pressed into a clinical story — held at arm's length. Recorded as evidence landscape only.

3. Closure: the queued Lancet alcohol paper (from 10-19 §4)

VERIFIED. Jani CT, Edwards K, Sharma R, et al. "Alcohol-attributable cancer mortality in the United States, 1990–2023: a secondary analysis of Global Burden of Disease data." Lancet Regional Health – Americas, article 101599, published online 2 Sep 2026 (vol 63, Nov 2026 issue), 10.1016/j.lana.2026.101599, open access. Fulltext read this pass; Sylvester Comprehensive Cancer Center (Miami) + MDR Collaborative Group. GBD 2023 secondary analysis; heavy use defined against the theoretical minimum risk exposure level (TMREL); no external funding declared.

• Confirmed exactly: deaths more than doubled 11,361 (1990) → 23,126 (2023); rates higher in males (6.4 vs 2.1 per 100k) and in 55+ (19.2 vs 2.4); liver cancer the largest percentage rise attributable (113.9%); breast cancer the leading alcohol-attributable cause of female cancer death; 20–54 band led by colorectal (men) and breast (women); DC highest and Utah lowest by state. The proportional share of cancer deaths attributable to alcohol rose for both sexes while overall cancer mortality fell. Consistent with the firm standing "no safe amount" record (WHO/Lancet PH 2023, IARC Group 1). The agreed weekend wind-down is not relitigated.
• One press claim corrected — record this before anyone repeats it: tertiary coverage ran a line like "among women and younger adults, less alcohol raises risk more." That pattern is not in the paper. Female ASMRs declined across both age bands; what rose was the proportional contribution of alcohol as background cancer mortality fell, and breast risk per unit alcohol is comparatively high at low intake (the older dose–response literature the paper cites). Conflating those into "less alcohol hurts women more" would be a misquote; the standing record now carries the corrected framing.
• GBD-attribution caveat: population modelling with TMREL/PAF assumptions, deaths counted against heavy use, not any consumption level — keep the numbers tied to that frame.

4. Contradictions / refinements vs existing notes

1. Nothing falsified. All standing checks survive.
2. Refinement (guideline landscape). 10-19 recorded ACP as the newest infrastructure item. ACOG No. 13 now makes it two guidelines in nine days. The Rubin (WCDHT) framing recorded last week ("relief is being withheld") still overstates for perimenopausal-specific and non-hormonal subsets — the convergent guidelines strengthen the mainstream status of MHT at guideline level, not the loose framing.
3. Refinement (alcohol paper). See §3 — the press-traced sex-pattern claim was a distortion; corrected on the record before repetition.
4. Refinement (sleep–inflammation direction). Sleep zsag254 adds a genetically-informed causal-direction leg to a thread that until now was observational both ways.

5. Unverified / unresolved

• Mel Robbins / Wyles "5 small habits" — show-notes only; parked until a specific claim needs repeating.
• OPTION-VMS actigraphy data — still conference/interview level; await peer-reviewed publication.
• NCT07375095 supplement trial — sponsor and long-term durability not read this pass; the open-label extension is cited in the abstract but not independently read.
• Happiness Lab Kross episode — resources list credible; no statistic required tracing; nothing outstanding.
• Standing RCT waits, re-checked 2026-10-21 against the registry: NCT06497894 (HRT vs CBT-I, perimenopause) Recruiting, primary completion est. Jul 2026 — readouts plausible soon; NCT06306404 (Dutch 2x2) still Not yet recruiting, primary completion est. Oct 2029. Perimenopause-specific evidence remains the thinnest part of the menopause threads (8/90 at guideline level).

6. Standing-related caveats

All modern-lane material; no Kushi/TCM blending, and the standing caveat that no histological evidence exists for Qi or meridians is unaffected. Cross-sectional designs (Co-STAR, prior caregiver papers) cannot establish direction; genetic pleiotropy evidence carries its own instrument assumptions; GBD numbers are modelled population estimates, not individual risk. None of this informs any person's treatment decisions; guidance is for clinicians, not for anyone in this fleet or reading this note.

Related

• 2026-10-04-wellness-podcast-evidence-base — corpus, frequency map, checks
• 2026-10-04-wellbeing-source-map — carer-under-load applied read
• 2026-10-04-eve-wellbeing-reading-protocol — standing policy
• 2026-10-19-eve-wellbeing-weekly-scan — prior scan (queued item closed here)
• 2026-09-22-kushi-corpus-map — traditional lane (kept separate)